Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Research analysts at HC Wainwright lifted their Q2 2025 earnings per share estimates for shares of Roivant Sciences in a note issued to investors on Monday, August 19th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.33) for the quarter, up from their prior estimate of ($0.36). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Roivant Sciences' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Roivant Sciences' Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.14) EPS, Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.26) EPS.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.33. The business had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a net margin of 3,484.86% and a negative return on equity of 25.05%. Roivant Sciences's revenue for the quarter was up 155.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.38) earnings per share.
A number of other equities analysts have also recently issued reports on ROIV. Cantor Fitzgerald reiterated an "overweight" rating on shares of Roivant Sciences in a report on Tuesday, June 18th. Piper Sandler upped their target price on Roivant Sciences from $20.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $17.10.
Read Our Latest Analysis on ROIV
Roivant Sciences Price Performance
NASDAQ:ROIV traded down $0.11 during midday trading on Thursday, hitting $11.68. The company had a trading volume of 3,293,992 shares, compared to its average volume of 5,738,667. The stock's fifty day moving average price is $10.91 and its 200-day moving average price is $10.93. Roivant Sciences has a 52-week low of $8.24 and a 52-week high of $13.24. The company has a quick ratio of 25.24, a current ratio of 25.24 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $8.63 billion, a PE ratio of 2.33 and a beta of 1.24.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP raised its holdings in shares of Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company's stock valued at $243,110,000 after acquiring an additional 3,000,000 shares in the last quarter. Vanguard Group Inc. increased its position in Roivant Sciences by 14.6% during the 1st quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company's stock valued at $85,441,000 after purchasing an additional 1,030,681 shares during the period. DME Capital Management LP raised its holdings in Roivant Sciences by 14.8% in the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company's stock worth $50,852,000 after purchasing an additional 620,470 shares in the last quarter. Norges Bank purchased a new stake in shares of Roivant Sciences in the 4th quarter worth about $41,506,000. Finally, BlackBarn Capital Partners LP boosted its stake in shares of Roivant Sciences by 63.1% during the 2nd quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company's stock valued at $32,767,000 after purchasing an additional 1,199,406 shares in the last quarter. Institutional investors own 64.76% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
